Review of environmental strategy UCB

Esta página solo está disponible en inglés. Para más información en español, no dude en contactar con nosotros.

UCB (http://www NULL.ucb NULL.com) is a global biopharma company focused on severe diseases in two therapeutic areas: central nervous system and immunology.  Operating in approximately 40 countries, UCB aspires to be a patient-centric biopharmaceutical leader transforming the lives of people living with severe diseases. In de context of the implementation of an environmental strategy, UCB defined six strategic pillars with corresponding key performance indictors (KPIs) ensuring regulatory compliance.

Ecomatters has performed a general review of UCB’s environmental strategy. We have assessed UCB’s six strategic pillars and coverage of the reported key performance indicators. Further, we conducted benchmarking of peer companies based on publicly reported information. Based on the peer review and standard reporting framework requirements (the Global Reporting Initiative and the EU Eco-Management and Audit Scheme), we proposed new KPIs and made recommendations to increase UCB’s “Environmental performance”.